Novel supreme drug-eluting stents with early synchronized antiproliferative drug delivery to inhibit smooth muscle cell proliferation after drug-eluting stents …
AJ Lansky, DJ Kereiakes, A Baumbach, S Windecker… - Circulation, 2021 - Am Heart Assoc
Background: Accelerated endothelial healing after targeted antiproliferative drug delivery
may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel …
may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel …
Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)
In the Targeted therapy with a localised abluminal coated, low-dose sirolimus-eluting,
biodegreadable polymer coronary stent (TARGET; NCT02520180) All Comers trial the …
biodegreadable polymer coronary stent (TARGET; NCT02520180) All Comers trial the …
[PDF][PDF] Polymers, thickness, dosage: just pieces of the whole puzzle
V Paradies, M Maurina - … : journal of EuroPCR in collaboration with …, 2023 - pcronline.com
Cardiovascular disease remains a significant global health concern, and percutaneous
coronary intervention (PCI) has undergone remarkable advancements, transforming the …
coronary intervention (PCI) has undergone remarkable advancements, transforming the …
[PDF][PDF] Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent-five-year results of the TARGET All …
AJ Lansky, B Xu, A Baumbach, H Kelbæk… - …, 2023 - microport.com
Background: In the prospective, multicentre, randomised TARGET All Comers study,
percutaneous coronary intervention (PCI) with the FIREHAWK biodegradable-polymer …
percutaneous coronary intervention (PCI) with the FIREHAWK biodegradable-polymer …
[HTML][HTML] Coronary interventions in 2020: the year in review: Coronary interventions in 2020
M Lunardi, C Gao, H Hara, M Ono, H Kawashima… - …, 2021 - ncbi.nlm.nih.gov
The coronavirus disease 2019 (COVID-19) pandemic represented–and is still representing–
a challenge for clinical research which has never been seen before1. In a context where …
a challenge for clinical research which has never been seen before1. In a context where …